Ramat Gan, Tel Aviv, Israel Clal Biotechnology Industries is the famous VC, which was founded in 1998. The company was established in Asia in Israel. The main office of represented VC is situated in the Ramat Gan.
Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Sight Diagnostics, Cadent Therapeutics, Elicio Therapeutics We can highlight the next thriving fund investment areas, such as Medical Device, Pharmaceutical. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the location of its establishment and the land of its numerous investments - Israel.
The usual things for fund are deals in the range of 10 - 50 millions dollars. This Clal Biotechnology Industries works on 12 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2013. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. The average startup value when the investment from Clal Biotechnology Industries is 100-500 millions dollars. The increased amount of exits for fund were in 2018.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Clal Biotechnology Industries, startups are often financed by Yissum Technology Transfer Company of the Hebrew University, Auriga Partners, Ziegler Meditech Equity Partners. The meaningful sponsors for the fund in investment in the same round are Yissum Technology Transfer Company of the Hebrew University, Pontifax, Technion Research & Development Foundation. In the next rounds fund is usually obtained by Yissum Technology Transfer Company of the Hebrew University, Wellington Management, Technion Research & Development Foundation.
We also calculated 2 valuable employees in our database.
Related Funds
Funds with similar focus
| Fund Name | Location |
| ACE Capital | Taichung, Taiwan |
| Aegis Investment Partners | - |
| Alberts Impact Capital | Australia, New South Wales, Sydney |
| Biyun Technology | - |
| Cultivian Sandbox Ventures | Chicago, Illinois, United States |
| DC Capital Partners | Alexandria, United States, Virginia |
| Deutsche Bank Securities | New York, New York, United States |
| Diamondhead Ventures | California, Menlo Park, United States |
| Dian Diagnostics | China, Hangzhou, Zhejiang |
| Emergent Technology Holdings | Houston, Texas, United States |
| Friulia Finanziaria FVG | Friuli-Venezia Giulia, Italy, Trieste |
| Kingsbrook Partners | New York, New York, United States |
| Muse Capital | California, Los Angeles, United States |
| Ningbo Huiya | China, Ningbo, Zhejiang |
| Palantir Capital | California, Rancho Santa Fe, United States |
| Qiandao Fund | Beijing, Beijing, China |
| RTS Ventures | - |
| Serent Capital | California, San Francisco, United States |
| Unisedu | Beijing, China, Haidian |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cadent Therapeutics | $15M | 29 Apr 2020 | Cambridge, Massachusetts, United States | ||
Elicio Therapeutics | $33M | 02 Oct 2019 | Cambridge, Massachusetts, United States | ||
Pi-Cardia | $10M | 07 Jan 2016 | Tel Aviv District | ||
Neon Therapeutics | $55M | 01 Oct 2015 | Cambridge, Massachusetts, United States | ||
Sight Diagnostics | $6M | 01 Nov 2014 | Tel Aviv-Yafo, Tel Aviv District, Israel | ||
Cadent Therapeutics | $6M | 21 Jun 2013 | Cambridge, Massachusetts, United States | ||
Avraham Pharmaceuticals | $9M | 13 Jul 2010 | Israel, North District, Israel | ||
ProtAb | $4M | 23 Apr 2010 | Jerusalem, Jerusalem District, Israel |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cadent Therapeutics | $15M | 29 Apr 2020 | Cambridge, Massachusetts, United States | ||
Elicio Therapeutics | $33M | 02 Oct 2019 | Cambridge, Massachusetts, United States | ||
Pi-Cardia | $10M | 07 Jan 2016 | Tel Aviv District | ||
Neon Therapeutics | $55M | 01 Oct 2015 | Cambridge, Massachusetts, United States | ||
Sight Diagnostics | $6M | 01 Nov 2014 | Tel Aviv-Yafo, Tel Aviv District, Israel | ||
Cadent Therapeutics | $6M | 21 Jun 2013 | Cambridge, Massachusetts, United States | ||
Avraham Pharmaceuticals | $9M | 13 Jul 2010 | Israel, North District, Israel | ||
ProtAb | $4M | 23 Apr 2010 | Jerusalem, Jerusalem District, Israel |
